Cargando…
Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity
Diabetes mellitus (DM) increases risk for pulmonary tuberculosis (TB) and adverse treatment outcomes. Systemic hyper-inflammation is characteristic in people with TB and concurrent DM (TBDM) at baseline, but the impact of TB treatment on this pattern has not been determined. We measured 17 plasma cy...
Autores principales: | Kumar, Nathella Pavan, Fukutani, Kiyoshi F, Shruthi, Basavaradhya S, Alves, Thabata, Silveira-Mattos, Paulo S, Rocha, Michael S, West, Kim, Natarajan, Mohan, Viswanathan, Vijay, Babu, Subash, Andrade, Bruno B, Kornfeld, Hardy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660216/ https://www.ncbi.nlm.nih.gov/pubmed/31271354 http://dx.doi.org/10.7554/eLife.46477 |
Ejemplares similares
-
Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed sputum culture conversion in pulmonary tuberculosis
por: Kumar, Nathella P., et al.
Publicado: (2019) -
Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity Are Associated With Lung Pathology and Bacterial Burden
por: Pavan Kumar, Nathella, et al.
Publicado: (2019) -
Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy
por: Kumar, Nathella Pavan, et al.
Publicado: (2019) -
Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment
por: Kumar, Nathella P., et al.
Publicado: (2018) -
Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications
por: Prada-Medina, Cesar A., et al.
Publicado: (2017)